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Abstract
OBJECTIVE—Many societies recommend using estimated glomerular filtration rate (eGFR) 
rather than serum creatinine (sCr) to determine metformin eligibility. We examined the potential 
impact of these recommendations on metformin eligibility among U.S. adults.
RESEARCH DESIGN AND METHODS—Metformin eligibility was assessed among 3,902 
adults with diabetes who participated in the 1999–2010 National Health and Nutrition 
Examination Surveys and reported routine access to health care, using conventional sCr thresholds 
(eligible if <1.4 mg/dL for women and <1.5 mg/dL for men) and eGFR categories: likely safe, ≥45 
mL/min/1.73 m2; contraindicated, <30 mL/min/1.73 m2; and indeterminate, 30–44 mL/min/1.73 
m2). Different eGFR equations were used: four-variable MDRD, Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) creatinine (CKD-EPIcr), and CKD-EPI cystatin C, as 
well as Cockcroft-Gault (CG) to estimate creatinine clearance (CrCl). Diabetes was defined by 
self-report or A1C ≥6.5% (48 mmol/mol). We used logistic regression to identify populations for 
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whom metformin was likely safe adjusted for age, race/ethnicity, and sex. Results were weighted 
to the U.S. adult population.
RESULTS—Among adults with sCr above conventional cutoffs, MDRD eGFR ≥45 mL/min/1.73 
m2 was most common among men (adjusted odds ratio [aOR] 33.3 [95%CI 7.4–151.5] vs. 
women) and non-Hispanic Blacks (aOR vs. whites 14.8 [4.27–51.7]). No individuals with sCr 
below conventional cutoffs had an MDRD eGFR <30 mL/min/1.73 m2. All estimating equations 
expanded the population of individuals for whom metformin is likely safe, ranging from 86,900 
(CKD-EPIcr) to 834,800 (CG). All equations identified larger populations with eGFR 30–
44mL/min/1.73 m2, for whom metformin safety is indeterminate, ranging from 784,700 (CKD-
EPIcr) to 1,636,000 (CG).
CONCLUSIONS—The use of eGFR or CrCl to determine metformin eligibility instead of sCr 
can expand the adult population with diabetes for whom metformin is likely safe, particularly 
among non-Hispanic blacks and men.
Healthy People 2020 goals include developing strategies for safe and effective glycemic 
control (1). One key strategy to attain this goal is to promote the use of metformin. 
Compared with other antidiabetes drugs, metformin is associated with decreased risk of 
cardiovascular events, progression of chronic kidney disease (CKD), and death (2,3). Also, 
it is well recognized that metformin has a better safety profile than other medications; in 
particular, it does not cause hypoglycemia, a common and potentially dangerous adverse 
effect of insulin secretagogues (4).
There is considerable reluctance, however, in using metformin among patients with CKD. 
Early pharmacokinetic studies demonstrated a prolonged half-life of metformin among 
individuals with severely impaired kidney function, placing them at heightened risk of lactic 
acidosis, a very rare (3.3–4.3 cases/100,000 patient-years) but serious metabolic 
complication that can occur in the setting of metformin accumulation (5). Thus, the U.S. 
Federal Drug Administration (FDA) has stated that metformin is contraindicated among 
individuals with kidney disease, “suggested by serum creatinine (sCr) ≥1.4 mg/dL for 
women and ≥1.5 mg/dL for men, or abnormal creatinine clearance (CrCl), which may result 
from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and 
septicemia” (6).
As the benefits of metformin have become more widely appreciated, there has been an 
ongoing debate as to whether these sCr thresholds are too restrictive and whether the 
benefits of metformin outweigh potential harm among individuals with mild-to-moderate 
CKD. At the same time, evidence has accumulated that sCr leads to substantial 
misclassification in identifying individuals with CKD and that estimated glomerular 
filtration rate (eGFR) is a more accurate estimation of an individual’s kidney function. In 
2012, the American Diabetes Association, Kidney Disease Improving Global Outcomes, 
European Association for the Study of Diabetes and U.K. National Institute for Health and 
Clinical Excellence all recommended metformin as a first-line agent for diabetes treatment 
among individuals with mild CKD, defined by eGFR ≥45 mL/min/1.73 m2, and stated not to 
use metformin among individuals with severe CKD, defined by eGFR < 30 mL/min/1.73 m2 
(7–9). Because robust safety data are lacking for individuals with moderate CKD, defined by 
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an eGFR 30–44 mL/min/1.73 m2, these societies recommended cautious use of metformin 
for individuals within this range, with frequent review and monitoring of kidney function.
Safely expanding metformin use among individuals with mild CKD may help improve 
outcomes among U.S. adults with diabetes. Our goals with this study were as follows: 1) to 
determine prevalence and trends of metformin use among U.S. adults with diabetes from 
1999 to 2010, 2) to identify subpopulations of U.S. adults with diabetes for whom 
metformin is likely safe when implementing eGFR rather than conventional sCr thresholds, 
and 3) to determine whether different GFR- or CrCl-estimating equations could have 
substantial impact on the number of individuals who would be considered safe candidates 
for metformin use.
RESEARCH DESIGN AND METHODS
Study Design
The National Health and Nutrition Examination Survey (NHANES) is conducted by the 
Centers for Disease Control and Prevention’s National Center for Health Statistics to 
examine trends in disease prevalence in cross-sectional representative samples of 
noninstitutionalized U.S. civilian residents (10). Survey data, released every 2 years, are 
collected during a standardized in-home interview and a physical examination/specimen 
collection at a mobile examination center.
Study Population
We examined data from 1999–2010 NHANES. The total number of adult (≥20 years) 
nonpregnant NHANES study participants with diabetes, defined by self-report or an A1C 
≥6.5% (48 mmol/mol), was 4,324. We excluded individuals who had missing demographic 
data (n = 189) and those who did not report a routine site for health care (n = 241). These 
restrictions allowed the study population (final n = 3,902) to represent a group of individuals 
with a high likelihood of receiving diabetes treatment at a routine site of health care. All 
NHANES participants had given informed consent according to a protocol approved by an 
institutional review board (10).
Definitions
Metformin eligibility was defined using conventional sCr cutoffs: eligible if sCr < 1.4 
mg/dL among women and < 1.5 mg/dL among men and ineligible if sCr ≥1.4 mg/dL among 
women and ≥1.5 mg/dL among men. Safe eGFR thresholds for metformin use were 
according to recent recommendations from American and European societies: likely safe if 
eGFR ≥45 mL/min/1.73 m2, contraindicated if eGFR < 30 mL/min/1.73 m2, and 
indeterminate if eGFR 30–44 mL/min/1.73 m2. eGFR was calculated using different 
equations: 1) four-variable MDRD study equation for calibrated sCr level (11), 2) CKD-EPI 
creatinine (CKD-EPIcr) equation (12), and 3) 2012 CKD-EPI cystatin C (CKD-EPIcys) 
equation (13). Creatinine clearance (CrCl) was estimated by the Cockcroft-Gault (CG) 
equation using actual body weight (14).
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Self-reported sociodemographics (age, sex, race/ethnicity, education, income), access to care 
(health insurance status, routine site for medical care), diagnoses (hypertension, diabetes 
mellitus), and type of antidiabetes medications (from prescription bottles provided by 
participants) were obtained during NHANES interviews. Blood pressure was measured 
during the mobile examination clinic visit; the mean of all measurements (up to four) was 
used. sCr was measured by the modified kinetic method of Jaffe, corrected for different 
analyzers and calibrated using isotope dilution mass spectrometry, with coefficients of 
variation ranging from 1.9 to 4.3 (15). Serum cystatin C was measured with the automated 
particle-enhanced nephelometric Dade Behring N Latex assay run on the Dade Behring 
Nephelometer II (16). The NHANES cystatin C assay had an intra-assay imprecision of 2.0–
3.0% coefficient of variation and an interassay imprecision of 3.2–4.4% coefficient of 
variation. Random spot urine albumin and creatinine levels were measured using single 
frozen specimens from each participant. Urine albumin was measured using a solid-phase 
fluorescence immunoassay; urine creatinine was measured using the modified Jaffe kinetic 
method. Albuminuria and urine creatinine were corrected according to NHANES 
documentation to allow for comparison across all 12 years (17). Serum A1C was measured 
by high-performance liquid chromatography, with a maximum bias of ±0.35% and a 
precision that does not exceed an SD of 0.229.
Statistical Methods
Participant characteristics were compared by metformin eligibility by χ2 and Wilcoxon rank-
sum tests. Prevalence of diabetes medication use and trends over time were estimated 
overall and by NHANES survey year. Variance of proportions was estimated with Taylor 
series linearization. Multivariable logistic regression was used to identify populations 
eligible for metformin (i.e., eGFR ≥ 45 mL/min/1.73 m2) among individuals with creatinine 
levels above conventional sCr cutoffs. Models were adjusted for age, sex, and race/ethnicity. 
Impact of different kidney function–estimating equations on the number of individuals who 
would be considered safe candidates for metformin use was calculated overall and by age, 
sex, and race/ethnicity. For these analyses, the study population was restricted to 1999–2002 
adult NHANES participants with diabetes and self-reported routine access to care, as 
cystatin C was only measured during those years.
Sensitivity analyses with different study populations were performed to assess robustness of 
the results. First, we restricted the study population to individuals who self-reported diabetes 
only (vs. self-report and a laboratory-based definition of diabetes), increasing the likelihood 
that they would have an opportunity to be treated with antidiabetes medications (n = 3,214). 
Second, we restricted the study population to 2005–2010 NHANES participants to create a 
more contemporary cohort of patients eligible for metformin (n = 1,412). Third, we 
restricted the study population to individuals who self-reported diabetes between 2005 and 
2010 NHANES (n = 1,171). All analyses were performed using the Survey Procedure 
commands in SAS, version 9.3 (SAS Institute, Cary, NC) using clusters, strata, and weights 
to obtain nationally representative population estimates.
Tuot et al. Page 4














Characteristics of the Study Population
Among NHANES adults with diabetes and routine access to care, 8.8% (study N = 342; 
estimated N = 1,328,400) were ineligible for metformin by conventional sCr thresholds and 
83.8% (study N = 3,269, estimated N = 16,308,600) were eligible for metformin. A total of 
291 individuals did not have creatinine data. Compared with individuals eligible for 
metformin, those ineligible were older and more likely to be non-Hispanic black or to have a 
yearly family income less than $45,000. There was a small but statistically significant higher 
prevalence of having health insurance among individuals not eligible for metformin. 
Prevalence of hypertension and macroalbuminuria was greater in those not eligible for 
metformin; BMI and glycemic control were similar in the two groups (Table 1).
Metformin Use Overall and by sCr Versus eGFR Categories
Across all 12 years, 66.4% of adults with diabetes were treated with a diabetes medication 
with a statistically significant increase over time: from 61.3% in 1999–2000 to 69.7% in 
2009–2010 (Ptrend = 0.03) (Fig. 1). Metformin use among persons with diabetes and a 
routine site for health care substantially increased over time, from 26.1 to 44.5% (Ptrend < 
0.001). Over the same period, concomitantly decreasing use of sulfonylureas and 
thiolidazinediones was noted, though these trends were nonsignificant.
The increase in metformin use between 1999 and 2010 was most pronounced among 
individuals with sCr ≤1.5 mg/dL and those with an MDRD eGFR ≥60 mL/min/1.73 m2 
(Supplementary Fig. 1). Between 2007 and 2010, an increase in metformin use among 
individuals with an eGFR 45–59 mL/min/1.73 m2 and a decrease in metformin use among 
individuals with an eGFR 30–44 mL/min/1.73 m2 were also noted (Supplementary Fig. 2).
Combining all 12 years of data, among individuals who were FDA eligible for metformin by 
conventional sCr thresholds, 40.7% (study N = 1,331, estimated N = 6,517,600) self-
reported metformin use (Table 2). The majority of these individuals had an MDRD eGFR 
≥45 mL/min/1.73 m2. Among individuals who were FDA ineligible for metformin by 
conventional sCr thresholds, 15.5% (study N = 53, estimated N = 182,500) self-reported 
metformin use (Table 3). Among those who self-reported metformin use, 26.0% had an 
MDRD eGFR ≥45 mL/min/1.73 m2 and 21.2% had an MDRD eGFR 30–44 mL/min/1.73 
m2. Comparable results were noted when the study population was restricted to 1) adults 
with diabetes defined by self-report only, 2) adult NHANES participants from 2005 to 2010, 
and 3) adult NHANES participants from 2005 to 2010 with diabetes defined by self-report 
only (data not shown).
Individuals for Whom Metformin Is Likely Safe Despite Being FDA Ineligible
Among individuals ineligible for metformin using conventional sCr thresholds, 14.6% 
(study N = 50, estimated N = 148,700) had an MDRD eGFR ≥45 mL/min/1.73 m2 and 50% 
(study N = 170; estimated N = 734,900) had an MDRD eGFR 30–44 mL/min/1.73 m2, 
representing groups for whom metformin is likely safe and indeterminate, respectively. Only 
35.7% (study N = 122, estimated N = 444,800) of individuals in eligible for metformin using 
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conventional thresholds had an MDRD eGFR < 30 mL/min/1.73 m2, representing a 
population for whom metformin would be contraindicated by eGFR category (Table 4). 
Individuals for whom metformin would likely be safe because of an MDRD eGFR ≥45 
mL/min/1.73 m2 were predominantly men (adjusted odds ratio [aOR] vs. women 33.3 [95% 
CI 7.4–151.5]), < 60 years of age (aOR vs. ≥60 years 6.3 [1.26–31.7]), and non-Hispanic 
black (aORvs. whites 14.8 [4.27–51.7]) compared with individuals with an MDRD eGFR < 
45 mL/min/1.73 m2. There were no differences in BMI, glycemic control, or prevalence of 
hypertension across eGFR categories. Comparable results were noted when the study 
population was restricted to 1) adults with diabetes defined by self-report only, 2) adult 
NHANES participants from 2005–2010, and 3) adult NHANES participants from 2005 to 
2010 with diabetes defined by self-report only (data not shown).
Individuals for Whom Metformin May Not be Safe Despite Being FDA Eligible
Among individuals eligible for metformin using conventional sCr thresholds, no one had an 
MDRD eGFR < 30 mL/min/1.73 m2. Over 98% (study N = 3,216, estimated N = 
16,037,300) had an MDRD eGFR ≥45 mL/min/1.73 m2, and 1.6% (study N = 53, estimated 
N = 271,300) had an MDRD eGFR 30–44 mL/min/1.73 m2, representing populations for 
whom metformin is likely safe and indeterminate, respectively (Supplementary Table 1). 
Comparable results were noted when the study population was restricted to 1) adults with 
diabetes defined by self-report only, 2) adult NHANES participants from 2005–2010, and 3) 
adult NHANES participants from 2005–2010 with diabetes defined by self-report only (data 
not shown).
Impact of Different GFR- and CrCl-Estimating Equations on Metformin Eligibility
All GFR- and CrCl-estimating equations expanded the pool of eligible metformin users 
compared with sCr. The magnitude of this change varied by equation, with national 
estimates ranging from 86,900 (CKD-EPIcr) to 834,800 (CG) (Supplementary Table 2). 
Consistent across all estimating equations, each subpopulation was predominantly male and 
non-Hispanic black (data not shown). For example, CKD-EPIcr expanded the national 
population of individuals eligible for metformin with an eGFR ≥45 mL/min/1.73 m2 by 
86,900 individuals, 100% of whom were male and 67% of whom were non-Hispanic black. 
Each estimating equation identified a much larger population of individuals for whom 
metformin safety was indeterminate (eGFR 30–44 mL/min/1.73 m2). National estimates of 
this population ranged from 784,700 (CKD-EPIcr) to 1,636,000 (CG) (Supplementary Table 
2).
CONCLUSIONS
This study has three key findings. First, although metformin use has increased in the past 
decade for treatment of the general population with type 2 diabetes, it remains underused 
among individuals with diabetes and mild kidney disease. Second, implementing eGFR or 
CrCl rather than sCr thresholds to determine individual eligibility for metformin could 
considerably expand the population eligible for its use, particularly among non- Hispanic 
blacks and men. Third, while various GFR- and CrCl-estimating equations identify different 
populations of individuals eligible/ineligible for metformin and all expand the population of 
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people with diabetes for whom metformin is likely safe, they also identify a large population 
of individuals for whom metformin safety remains unclear based on current U.S. 
recommendations.
The trend toward greater metformin use over the past decade is positive, as metformin 
remains the antidiabetes medication associated with the highest efficacy, the best 
cardiovascular profile, and the fewest unwanted side effects (2,4,18). Nationally 
representative data have recently demonstrated a decrease in diabetes complications over the 
same period (19). These improvements reflect advances in acute clinical care as well as 
chronic disease care and risk factor control. While speculative, it is possible that greater use 
of diabetes medications, and metformin in particular, for tighter glycemic control in the late 
1990s and early 2000s may have contributed at least in part to these important public health 
gains.
Despite potential benefits, metformin remains underused among individuals with diabetes 
and mild kidney disease, who are at even greater risk of cardiovascular morbidity and 
mortality compared with the general population with diabetes (20). Creatinine thresholds are 
problematic for defining CKD. Creatinine production correlates with muscle mass and can 
underestimate or overestimate kidney function among individuals with muscle mass that 
differs from the population average. Estimates of GFR based on sCr, race, age, and sex are 
more clinically useful measures of kidney function, though they, too, must be cautiously 
interpreted among patients at anthropomorphic extremes. Nevertheless, these equations are 
recommended for medication dosing by several national and international nephrology 
societies. The Kidney Disease Outcomes Quality Initiative and Kidney Disease Improving 
Global Outcomes, for example, both recommend using metformin as a first-line agent 
among individuals with an eGFR of ≥45 mL/min/1.73 m2 and to discontinue metformin 
definitively among individuals with an eGFR < 30 mL/min/1.73 m2 (8,21). While our data 
do not allow us to ascertain clinician behavior, the sharp drop in metformin use among 
individuals with an eGFR < 45 mL/min/1.73 m2 after 2007 compared with those with an 
eGFR ≥45 mL/min/1.73 m2 allows us to speculate that the recommended eGFR thresholds 
are gaining importance in determining metformin eligibility.
Replacing sCr thresholds with eGFR thresholds could expand the pool of patients for whom 
metformin is likely safe without creating substantial safety concerns. Notably, 18% of 
individuals newly eligible for metformin in our study had an A1C >9% (75 mmol/mol). 
While uncontrolled diabetes is associated with more rapid renal function decline, studies 
have quoted rates of renal function decline ranging from −1.26 mL/min/1.73 m2 per year to 
−3.24 mL/min/1.73 m2 per year (22). Assuming at least yearly or more frequent monitoring 
of renal function among these patients, these rates of decline do not likely pose safety 
concerns and should not be impediments to metformin prescription. Thus, our study 
suggests that the number of individuals eligible for metformin in the U.S. can be expanded 
by at least 104,000, if using MDRD eGFR to calculate kidney function. This is a 
conservative estimate, as it does not take into account individuals who might be eligible for 
metformin with an MDRD eGFR 30–44 mL/min/1.73 m2.
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Approximately 50% of individuals with an sCr above the conventional threshold of 
metformin eligibility and 1.7% of individuals with an sCr below the conventional threshold 
had an MDRD eGFR between 30–44 mL/min/1.73 m2. Individuals with diabetes and this 
level of kidney dysfunction are at higher risk of hypoglycemia, CKD progression, and 
mortality compared with individuals with less severe CKD, and may particularly benefit 
from metformin rather than a sulfonylurea or thiazolidinedione (23,24). Given the lack of 
robust data, current guidelines do not provide much guidance about metformin use in this 
population, though a few studies suggest its safety among individuals with a stable eGFR > 
30 mL/min/1.73 m2 (25). A randomized controlled trial is needed to clarify whether use of 
metformin in this subgroup would be safe and efficacious.
Importantly, the expanded pool of individuals for whom metformin is likely safe was 
predominantly male and non- Hispanic black. Prior European studies have documented that 
replacing creatinine thresholds with eGFR thresholds can minimize the number of males 
denied treatment with metformin (26,27). Our work builds upon these studies and identifies 
the potential impact of eGFR on metformin eligibility by race/ethnicity in addition to sex. 
Racial/ethnic disparities with respect to diabetes health outcomes are well recognized. Non-
Hispanic black Americans with diabetes have worse glycemic control than their non-
Hispanic white counterparts and have been demonstrated to shoulder a greater burden of 
diabetes complications, such as end-stage renal disease, retinopathy, neuropathy, and 
nontraumatic lower-extremity amputations (28–31). Paradoxically, recent studies have not 
shown differences in receipt of routine A1C testing, nephropathy screening, ormono-
filament foot examination between non- Hispanic blacks and non-Hispanic whites when 
accounting for individual patient and facility variables (32). Non-Hispanic blacks generally 
have higher sCr than individuals of other race/ethnicities (33). Relying on eGFR rather than 
creatinine thresholds to determine metformin eligibility and safety may thus help bridge the 
gap between the aforementioned process and outcome measures (34).
The ideal method for estimating kidney function is an area of active research, as all kidney 
function–estimating formulas have inherent shortcomings compared with the gold standard 
of measured GFR using urinary or plasma clearance of exogenous filtration markers (35). 
CG estimates of CrCl are frequently used by pharmacists to determine medication dosing 
(36). However, CrCl is not readily available to clinicians who prescribe metformin. The 
National Kidney Disease Education Program reports that most laboratories use the four-
variable MDRD and recommends it to determine medication safety (37). The newer CKD-
EPIcr (12) generally has less bias than the four-variable MDRD and is slowly gaining 
traction among U.S. nephrologists and clinical laboratories (38); however, some studies 
suggest that it may perform less well than the four-variable MDRD equation when 
estimating GFR among individuals with type 2 diabetes (39). Recent data suggest that 
cystatin C–based equations may reclassify individuals into less severe stages of CKD and 
are more highly correlated with health outcomes than creatinine-based eGFR among patients 
with CKD (40). CKD-EPIcys has thus been recommended for confirmation of CKD status 
for elderly individuals in whom creatinine-based equations may not be accurate (41). 
Discrepancies in medication dosing using different kidney function–estimating equations 
have been well documented, particularly for elderly patients (42–44). However, to our 
knowledge, only one study has demonstrated the potential impact of these discrepancies on 
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health outcomes (45). In our study, while the CG equation expanded the number of 
individuals eligible for metformin the most, it also appeared to be the most conservative 
equation, reclassifying even more individuals to subpopulations for whom metformin is not 
safe or indeterminate. This is consistent with data demonstrating that CG underestimates 
GFR among patients with type 2 diabetes and overt diabetic nephropathy (46,47). Without 
hard outcomes, it is difficult to identify which kidney function–estimating equation is 
optimal to use to guide clinical decision making. Prospective studies should clarify the role 
of each equation for evaluation of safety and efficacy of medication dosing, including 
metformin, among CKD patients.
There are several limitations to this study, notably that NHANES is not a clinical database 
and includes community-dwelling individuals who do not seek medical care. However, we 
restricted our study population to participants who self-reported a routine site for health care 
and found similar results when restricting the study population to individuals who were 
aware of their diabetes. We could not ascertain the reasoning behind low levels of 
metformin use. Specifically, we could not determine whether this was due to patient 
nonadherence or lack of provider prescription, perhaps owing to nonrenal clinical conditions 
that contraindicate the use of metformin, such as liver disease. Additionally, NHANES relies 
on single measurements of eGFR and urinary albumin, leading to possible misclassification.
In summary, we demonstrate that metformin use may be expanded among adults with 
diabetes and mild CKD by focusing on eGFR rather than sCr thresholds for prescribing 
purposes, per recent national and international recommendations. In so doing, we may help 
mitigate racial/ethnic disparities in diabetes management and outcomes for non-Hispanic 
blacks. Additional research is needed to identify the best kidney function–estimating 
equation for optimal use and dosing of metformin at point of care. Lastly, it is important to 
identify the safety and efficacy of metformin among individuals with eGFR 30–44 mL/min/
1.73 m2, as this represents another potential avenue to further enhance diabetes care for 
adults at high risk of cardiovascular complications.
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Table 1
Characteristics of adults with diabetes and routine access to care by conventional metformin eligibility status, 
NHANES 1999–2010
FDA ineligible:
sCr >1.4 mg/dL for women;
>1.5 mg/dL for men
FDA eligible:
sCr ≤1.4 mg/dL for women;








16,308,600 P (χ2or ANOVA)
Male sex 199 (58.2) 682,072 1,641 (50.2) 8,126,661 0.63
Age (years) <0.001
  20–39 3 (0.9) 13,763 206 (6.3) 1,518,262
  40–59 36 (10.5) 178,858 1,003 (30.7) 6,800,049
  60–69 107 (31.3) 388,365 1,041 (31.8) 4,071,965
  70+ 196 (57.3) 747,369 1,019 (31.2) 3,918,311
Race/ethnicity** 0.0007
  White 142 (41.5) 835,991 1,294 (39.6) 10,394,879
  Non-Hispanic black 124 (36.3) 314,372 817 (25.0) 2,510,790
  Mexican American 58 (17.0) 69,714 766 (23.4) 1,273,053
Yearly family income ($) 0.0001
  <20,000 124 (40.4) 456,578 954 (32.4) 3,606,754
  20,000–44,999 122 (39.7) 477,204 1,051 (35.6) 5,202,546
  45,000–74,999 41 (13.4) 164,698 531 (18.0) 3,082,007
  >75,000 20 (6.5) 109,762 419 (14.2) 3,061,184
Has health insurance 327 (95.61) 1,276,535 408 (12.6) 1,449,1185 0.01
More than high school education 137 (50.6) 632,030 1,431 (55.9) 9,133,441 0.007
Hypertension* 267 (78.8) 1,058,591 2,036 (67.7) 9,615,947 <0.001
Glycemic control: A1C 0.22
  <7% (<53 mmol/mol) 200 (58.7) 817,351 1,735 (53.2) 8,890,542
  7–<8% (53–63 mmol/mol) 74 (21.7) 284,722 688 (21.1) 3,389,353
  8–<9% (64–74 mmol/mol) 33 (9.7) 104,007 330 (10.1) 1,565,172
  ≥9% (>75 mmol/mol) 34 (10.0) 119,576 509 (15.6) 2,432,187
BMI (kg/m2), mean (SD) 32.6 (8.2) 33.02 (0.5) 32 (7.1) 32.65 (0.2) 0.51
MDRD eGFR (mL/min/1.73 m2), mean 
(SD)
32.8 (12.6) 32.99 (0.7) 84.94 (25.4) 84.47 (0.5) <0.001
Urine albumin-to-creatinine ratio (mg/g) <0.001
  ≤30 103 (33.9) 439,836 2,187 (68.4) 11,556,713
  31–299 111 (36.5) 434,403 788 (24.7) 3,585,717
  300–1,000 33 (10.9) 128,431 151 (4.7) 572,633
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FDA ineligible:
sCr >1.4 mg/dL for women;
>1.5 mg/dL for men
FDA eligible:
sCr ≤1.4 mg/dL for women;








16,308,600 P (χ2or ANOVA)
  >1,000 57 (18.8) 210,052 71 (2.2) 287,114
Data are n (%) or n unless otherwise indicated. Sample weights used to produce U.S. national estimates. Diabetes is self-reported or A1C ≥6.5%. 
Entire sample size = 3,902; sCr data are missing from 291 study participants.
*
Hypertension defined by average blood pressure >140/90 mm Hg or self-reported antihypertensive medication use.
**
“Other” not shown owing to small sample size but included in all analyses.
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Table 2
Metformin self-report among adults with diabetes and routine access to care who are FDA eligible for 
metformin by conventional sCr thresholds by eGFR category, NHANES 1999–2010
FDA eligible for metformin
(sCr <1.4 mg/dL for women; <1.5 mg/dL for men)
Overall study N
Metformin self-report
Study N % National estimate (n)
All 3,269 1,331 40.7 6,517,600
MDRD eGFR <30 mL/min/1.73 m2 0 0 0 0
MDRD eGFR 30–44 mL/min/1.73 m2 53 18 34.0 85,400
MDRD eGFR ≥45 mL/min/1.73 m2 3,216 1,313 40.8 6,432,200
Weights used to produce U.S. national estimates.
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Table 3
Metformin self-report among adults with diabetes and routine access to care who are FDA ineligible for 
metformin by conventional sCr thresholds by eGFR category, NHANES 1999–2010
FDA ineligible for metformin
(serum creatinine ≥1.4 mg/dL for women;
≥1.5 mg/dL for men)
Overall study N
Metformin self-report
Study N % National estimate (n)
All 342 53 15.5 182,500
MDRD eGFR <30 mL/min/1.73 m2 122 4 3.3 5,800
MDRD eGFR 30–44 mL/min/1.73 m2 170 36 21.2 120,800
MDRD eGFR ≥45 mL/min/1.73 m2 50 13 26.0 55,800
Weights used to produce U.S. national estimates.
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